New Type 2 drug shows promising trial results

A medication to treat Type 2 diabetes has significantly reduced blood sugar and body weight in participants of a late-phase clinical trial.

Eli Lilly’s Tirzepatide is in phase 3 development for blood glucose management in adults with Type 2 diabetes and for chronic weight management. It is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure, therefore, resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight.

Find out more HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags